Skip to search formSkip to main contentSkip to account menu

Olbetam

Known as: Olbemox 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Acute inflammation, and subsequent release of bacterial products (e.g. LPS), inflammatory cytokines, and stress… 
2014
2014
  • 2014
  • Corpus ID: 34850302
4.1. Therapeutic indications Olbetam is indicated as alternative or adjunct treatment to reduce triglyceride levels in patients… 
2000
2000
32 patients with hypertriglyceridemia, excessive hypertriglyceridemia, and combined hyperlipidemia, were treated with the… 
2000
2000
The interrelation was studied of processes of lipid peroxidation (LPO), the antioxidant system (AOS) with the level of endogenous… 
1995
1995
The effect of Olbetam on serum lipid and lipoproteins was studied in 30 diabetic patients with hyperlipidemia in four weeks trial… 
1995
1995
  • A. Scheen
  • Revue medicale de Liege
  • 1995
  • Corpus ID: 29783681
L'acipimox (Olbetam®), commercialise recemment par la firme Pharmacia, est un nouveau medicament hypolipidemiant, different des… 
1994
1994
BACKGROUND Hypertriglyceridaemia associated with low HDL-concentrations is considered an independent risk factor of ischaemic… 
1993
1993
  • R. Currie
  • The New Zealand medical journal
  • 1993
  • Corpus ID: 42429897
1991
1991
The objective of this work was to test in type II diabetics with hyperlipoproteinaemia the action of a new analogue of nicotinic… 
1990
1990
Twenty-one patients with type II hyperlipidaemia were treated with the nicotinic acid analogue, acipimox (Olbetam; Farmitalia…